CN117916240A - 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物 - Google Patents

用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物 Download PDF

Info

Publication number
CN117916240A
CN117916240A CN202280059585.7A CN202280059585A CN117916240A CN 117916240 A CN117916240 A CN 117916240A CN 202280059585 A CN202280059585 A CN 202280059585A CN 117916240 A CN117916240 A CN 117916240A
Authority
CN
China
Prior art keywords
formula
compound
cancer
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059585.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·阿尔马里奥
丹妮尔·德佩雷蒂
A·多梅尔格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN117916240A publication Critical patent/CN117916240A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280059585.7A 2021-07-16 2022-07-12 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物 Pending CN117916240A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305999.1 2021-07-16
EP21305999 2021-07-16
PCT/EP2022/069472 WO2023285466A1 (en) 2021-07-16 2022-07-12 Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy

Publications (1)

Publication Number Publication Date
CN117916240A true CN117916240A (zh) 2024-04-19

Family

ID=77126712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059585.7A Pending CN117916240A (zh) 2021-07-16 2022-07-12 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物

Country Status (7)

Country Link
US (1) US20240300956A1 (https=)
EP (1) EP4370518A1 (https=)
JP (1) JP2024525791A (https=)
CN (1) CN117916240A (https=)
AR (1) AR126471A1 (https=)
TW (1) TW202321245A (https=)
WO (1) WO2023285466A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011033230A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Dérivés de 5-phenyl-pyrazolopyridine, leur préparation et leur application en thérapeutique
CN102036959A (zh) * 2008-03-21 2011-04-27 赛诺菲-安万特 多取代的2-芳基-6-苯基咪唑并[1，2-a]吡啶衍生物及其制备方法和治疗用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3581380B2 (ja) * 1993-08-17 2004-10-27 富士写真フイルム株式会社 アゾメチン色素およびそれを含有する熱転写色素供与材料
US20040010056A1 (en) * 2002-06-28 2004-01-15 Konica Corporation Colored particle dispersion, ink jet ink, dye, and ink jet recording method
FR2928924B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
EP4370516A1 (en) * 2021-07-16 2024-05-22 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036959A (zh) * 2008-03-21 2011-04-27 赛诺菲-安万特 多取代的2-芳基-6-苯基咪唑并[1，2-a]吡啶衍生物及其制备方法和治疗用途
WO2011033230A1 (fr) * 2009-09-18 2011-03-24 Sanofi-Aventis Dérivés de 5-phenyl-pyrazolopyridine, leur préparation et leur application en thérapeutique

Also Published As

Publication number Publication date
US20240300956A1 (en) 2024-09-12
EP4370518A1 (en) 2024-05-22
TW202321245A (zh) 2023-06-01
WO2023285466A1 (en) 2023-01-19
JP2024525791A (ja) 2024-07-12
AR126471A1 (es) 2023-10-11

Similar Documents

Publication Publication Date Title
KR20210135561A (ko) 피라진 유도체 및 shp2 억제에서의 그의 적용
JP5808408B2 (ja) フタラジノンケトン誘導体、その製造法および医薬用途
US20100203113A1 (en) Wnt signalling inhibitors, and methods for making and using them
TW202128668A (zh) 并環類衍生物、其製備方法及其在醫藥上的應用
AU2015336458B2 (en) KCNQ2-5 channel activator
WO1998018765A1 (fr) Composes de 1-phenylpyrazole et leur application pharmaceutique
WO2004106325A1 (en) Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
WO2023280182A1 (zh) 作为kat6抑制剂的化合物
JP5695200B2 (ja) 複素環アミノベルバミン誘導体、その調製方法及び使用
CN107880038B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN115417867A (zh) 取代萘甲酰胺类衍生物及其医药用途
WO2016039398A1 (ja) 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
EP3119787A1 (en) Inhibitors of the wnt signalling pathways
CN118234727A (zh) 用于疗法的6H-咪唑并[1,2-a]吡咯并[2,3-e]吡啶衍生物
KR20200123184A (ko) 증식이상 장애를 치료하기 위한 물질 및 방법
KR20230106610A (ko) 치료제로서의 석시네이트 및 이의 결정 형태
CN117916240A (zh) 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物
CN110467616A (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110407839A (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2022022630A1 (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
WO2001005402A1 (en) Preventive and therapeutic agents for cancer
JP2022500423A (ja) エストロゲン受容体陽性乳癌の治療のための併用療法
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination